256 related articles for article (PubMed ID: 37253806)
1. Tumor cell-intrinsic and tumor microenvironmental conditions co-determine signaling by the glycoimmune checkpoint receptor Siglec-7.
van Houtum EJH; Kers-Rebel ED; Looman MW; Hooijberg E; Büll C; Granado D; Cornelissen LAM; Adema GJ
Cell Mol Life Sci; 2023 May; 80(6):169. PubMed ID: 37253806
[TBL] [Abstract][Full Text] [Related]
2. Siglec Signaling in the Tumor Microenvironment.
van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
Front Immunol; 2021; 12():790317. PubMed ID: 34966391
[TBL] [Abstract][Full Text] [Related]
3. Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.
Lustig M; Chan C; Jansen JHM; Bräutigam M; Kölling MA; Gehlert CL; Baumann N; Mester S; Foss S; Andersen JT; Bastian L; Sondermann P; Peipp M; Burger R; Leusen JHW; Valerius T
Front Immunol; 2023; 14():1178817. PubMed ID: 37346044
[TBL] [Abstract][Full Text] [Related]
4. Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment.
van de Wall S; Santegoets KCM; van Houtum EJH; Büll C; Adema GJ
Trends Immunol; 2020 Apr; 41(4):274-285. PubMed ID: 32139317
[TBL] [Abstract][Full Text] [Related]
5. Sialylated IgG in epithelial cancers inhibits antitumor function of T cells via Siglec-7.
Fan T; Liao Q; Zhao Y; Dai H; Song S; He T; Wang Z; Huang J; Zeng Z; Guo H; Zhang H; Qiu X
Cancer Sci; 2023 Feb; 114(2):370-383. PubMed ID: 36310398
[TBL] [Abstract][Full Text] [Related]
6. Unraveling Molecular Recognition of Glycan Ligands by Siglec-9 via NMR Spectroscopy and Molecular Dynamics Modeling.
Atxabal U; Nycholat C; Pröpster JM; Fernández A; Oyenarte I; Lenza MP; Franconetti A; Soares CO; Coelho H; Marcelo F; Schubert M; Paulson JC; Jiménez-Barbero J; Ereño-Orbea J
ACS Chem Biol; 2024 Feb; 19(2):483-496. PubMed ID: 38321945
[TBL] [Abstract][Full Text] [Related]
7. SIGLEC-5/14 Inhibits CD11b/CD18 Integrin Activation and Neutrophil-Mediated Tumor Cell Cytotoxicity.
Bouti P; Blans C; Klein BJAM; Shome D; Nadafi R; Van Houdt M; Schornagel K; Verkuijlen PJJH; Roos V; Reijmers RM; Van Bruggen R; Kuijpers TW; Matlung HL
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38138970
[TBL] [Abstract][Full Text] [Related]
8. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
Bärenwaldt A; Läubli H
Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
[No Abstract] [Full Text] [Related]
9. MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint.
Smith BAH; Deutzmann A; Correa KM; Delaveris CS; Dhanasekaran R; Dove CG; Sullivan DK; Wisnovsky S; Stark JC; Pluvinage JV; Swaminathan S; Riley NM; Rajan A; Majeti R; Felsher DW; Bertozzi CR
Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2215376120. PubMed ID: 36897988
[TBL] [Abstract][Full Text] [Related]
10. The ligand interactions of B cell Siglecs are involved in the prevention of autoimmunity to sialylated self-antigens and in the quality control of signaling-competent B cells.
Tsubata T
Int Immunol; 2023 Oct; 35(10):461-473. PubMed ID: 37504378
[TBL] [Abstract][Full Text] [Related]
11. Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.
Adams OJ; Stanczak MA; von Gunten S; Läubli H
Glycobiology; 2018 Sep; 28(9):640-647. PubMed ID: 29309569
[TBL] [Abstract][Full Text] [Related]
12. Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.
Daly J; Carlsten M; O'Dwyer M
Front Immunol; 2019; 10():1047. PubMed ID: 31143186
[TBL] [Abstract][Full Text] [Related]
13. The glycoimmune checkpoint receptor Siglec-7 interacts with T-cell ligands and regulates T-cell activation.
Stewart N; Daly J; Drummond-Guy O; Krishnamoorthy V; Stark JC; Riley NM; Williams KC; Bertozzi CR; Wisnovsky S
J Biol Chem; 2024 Feb; 300(2):105579. PubMed ID: 38141764
[TBL] [Abstract][Full Text] [Related]
14. Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2.
Wieboldt R; Sandholzer M; Carlini E; Lin CW; Börsch A; Zingg A; Lardinois D; Herzig P; Don L; Zippelius A; Läubli H; Mantuano NR
Cell Mol Immunol; 2024 May; 21(5):495-509. PubMed ID: 38448555
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic cancer-associated fibroblasts modulate macrophage differentiation via sialic acid-Siglec interactions.
Boelaars K; Rodriguez E; Huinen ZR; Liu C; Wang D; Springer BO; Olesek K; Goossens-Kruijssen L; van Ee T; Lindijer D; Tak W; de Haas A; Wehry L; Nugteren-Boogaard JP; Mikula A; de Winde CM; Mebius RE; Tuveson DA; Giovannetti E; Bijlsma MF; Wuhrer M; van Vliet SJ; van Kooyk Y
Commun Biol; 2024 Apr; 7(1):430. PubMed ID: 38594506
[TBL] [Abstract][Full Text] [Related]
16. Tools to study and target the Siglec-sialic acid axis in cancer.
Läubli H; Kawanishi K; George Vazhappilly C; Matar R; Merheb M; Sarwar Siddiqui S
FEBS J; 2021 Nov; 288(21):6206-6225. PubMed ID: 33251699
[TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of zoledronic acid through the sialic acid - Siglec axis for killing and reversal of M2 phenotypic tumor-associated macrophages - A promising cancer immunotherapy.
Tang X; Sui D; Liu M; Zhang H; Liu M; Wang S; Zhao D; Sun W; Liu M; Luo X; Lai X; Liu X; Deng Y; Song Y
Int J Pharm; 2020 Nov; 590():119929. PubMed ID: 33010395
[TBL] [Abstract][Full Text] [Related]
18. The sialoglycan-Siglec-E checkpoint axis in dexamethasone-induced immune subversion in glioma-microglia transwell co-culture system.
Wielgat P; Czarnomysy R; Trofimiuk E; Car H
Immunol Res; 2019 Oct; 67(4-5):348-357. PubMed ID: 31741237
[TBL] [Abstract][Full Text] [Related]
19. Sialylated glycoproteins as biomarkers and drivers of progression in prostate cancer.
Wen R; Zhao H; Zhang D; Chiu CL; Brooks JD
Carbohydr Res; 2022 Sep; 519():108598. PubMed ID: 35691122
[TBL] [Abstract][Full Text] [Related]
20. Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands.
Boelaars K; van Kooyk Y
Trends Cancer; 2024 Mar; 10(3):230-241. PubMed ID: 38160071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]